Sharon Longhurst
Direttore/Membro del Consiglio presso IDOGEN AB (PUBL)
Profilo
Sharon Longhurst is currently an Independent Director at Idogen AB and Elicera Therapeutics AB.
Previously, she worked as the Head-Chemistry, Manufacturing & Control at Mendus AB and as the Vice President-Development at Gadeta BV from 2021 to 2023.
Dr. Longhurst holds a doctorate degree from the University of Warwick and an undergraduate degree from the University of Surrey.
Posizioni attive di Sharon Longhurst
| Società | Posizione | Inizio |
|---|---|---|
| IDOGEN AB (PUBL) | Direttore/Membro del Consiglio | 12/05/2020 |
| ELICERA THERAPEUTICS AB | Direttore/Membro del Consiglio | 01/01/2024 |
Precedenti posizioni note di Sharon Longhurst
| Società | Posizione | Fine |
|---|---|---|
Gadeta BV
 Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Corporate Officer/Principal | 01/08/2023 |
| MENDUS AB | Corporate Officer/Principal | - |
Formazione di Sharon Longhurst
| University of Warwick | Doctorate Degree |
| University of Surrey | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| IDOGEN AB (PUBL) | Health Technology |
| MENDUS AB | Health Technology |
| ELICERA THERAPEUTICS AB | Health Technology |
| Aziende private | 1 |
|---|---|
Gadeta BV
Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Health Technology |
- Borsa valori
- Insiders
- Sharon Longhurst
